Pfizer buying Medivation in deal valued at about $14B (Update) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present


Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, August 23, 2016

Pfizer buying Medivation in deal valued at about $14B (Update)

financial news

 Aside from Xtandi, Pfizer Inc. said Medivation also has a promising pipeline of cancer drugs in late-stage clinical development. That includes the potential breast cancer treatment talazoparib and a potential lymphoma drug.

Talazoparib, an orally available poly-ADP ribose polymerase, or PARP, inhibitor, is currently in a Phase 3 clinical trial for the treatment of patients with gBRCA mutated breast cancer (i.e., advanced breast cancer in patients whose BRCA genes contain germline mutations). In addition, we are targeting a number of other solid tumor indications in which to investigate talazoparib, including breast (beyond gBRCA mutations), prostate, small cell lung, and ovarian cancers.
Note: gBRCA = BRCA1/2


Post a Comment

Your comments?